<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wang H</submitter><funding>National Natural Science Foundation of China</funding><funding>National Natural Science Foundation of China (National Science Foundation of China)</funding><pagination>16</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12769697</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>9(1)</volume><pubmed_abstract>Host-directed antibacterial compounds remain underdeveloped for intracellular pathogens. Here, we identify Dehydroevodiamine (DEHD) as a broad-spectrum host-directed antibiotics that inhibits intracellular bacterial replication (Salmonella, E. coli, S. aureus, etc.) and synergizes with antibiotics in vitro and in vivo. Structural analyses reveal DEHD directly binds MDM2 (KD=68.34 μM), activating the MDM2-P53-V-ATPases axis to maintain lysosomal acidity through V-ATPase activity and induce mTOR-dependent autophagy. This mechanism enhances antibiotic efficacy against resistant pathogens, reducing mortality from 90% to 10% in lethal murine infections. Our work establishes lysosomal activation via the MDM2-P53-V-ATPases axis as a potent host-directed strategy, with DEHD providing a promising l</pubmed_abstract><journal>Communications biology</journal><pubmed_title>MDM2-P53-V-ATPases axis driven by dehydroevodiamine to fight intracellular bacterial infection.</pubmed_title><pmcid>PMC12769697</pmcid><funding_grant_id>U22A20523</funding_grant_id><pubmed_authors>Xu L</pubmed_authors><pubmed_authors>Wang N</pubmed_authors><pubmed_authors>Kong L</pubmed_authors><pubmed_authors>He X</pubmed_authors><pubmed_authors>Ma H</pubmed_authors><pubmed_authors>Wang H</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Wang J</pubmed_authors><pubmed_authors>Niu X</pubmed_authors><pubmed_authors>Deng X</pubmed_authors><pubmed_authors>Wang L</pubmed_authors></additional><is_claimable>false</is_claimable><name>MDM2-P53-V-ATPases axis driven by dehydroevodiamine to fight intracellular bacterial infection.</name><description>Host-directed antibacterial compounds remain underdeveloped for intracellular pathogens. Here, we identify Dehydroevodiamine (DEHD) as a broad-spectrum host-directed antibiotics that inhibits intracellular bacterial replication (Salmonella, E. coli, S. aureus, etc.) and synergizes with antibiotics in vitro and in vivo. Structural analyses reveal DEHD directly binds MDM2 (KD=68.34 μM), activating the MDM2-P53-V-ATPases axis to maintain lysosomal acidity through V-ATPase activity and induce mTOR-dependent autophagy. This mechanism enhances antibiotic efficacy against resistant pathogens, reducing mortality from 90% to 10% in lethal murine infections. Our work establishes lysosomal activation via the MDM2-P53-V-ATPases axis as a potent host-directed strategy, with DEHD providing a promising l</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-06-06T11:08:01.434Z</modification><creation>2026-05-29T03:12:39.434Z</creation></dates><accession>S-EPMC12769697</accession><cross_references><pubmed>41390711</pubmed><doi>10.1038/s42003-025-09251-w</doi></cross_references></HashMap>